Bhami's Research Laboratory

What Bhami's Research Laboratory does

Bhami's Research Laboratory (BRL) is a privately held, Mangalore-based biotechnology company founded in 2013 that develops proprietary drug delivery platforms for biotherapeutics. Its two core technologies are HILOPRO®, a viscosity-reduction platform that uses GRAS excipients to enable subcutaneous delivery of monoclonal antibodies at concentrations up to 250 mg/mL with viscosity as low as 14 cP (validated on 9+ molecules including Trastuzumab, Rituximab, Bevacizumab, Etanercept and Cetuximab), and Evopep, an oral biologics delivery platform that has demonstrated 10–15% bioavailability in in-vivo animal studies—reported as at least 3x higher than Rybelsus® (oral semaglutide)—across peptides including Insulin, Semaglutide, Liraglutide, HGH, Octreotide and PTH. The technology is protected by a worldwide-granted patent on high-concentration protein formulations (US-granted, filed in 6 jurisdictions) and registered trademarks for HILOPRO® and Evopep, and has been validated by four major biopharma players.

BRL operates as a technology licensor rather than a product manufacturer, monetizing its platforms through upfront licensing fees, development-stage milestone payments, and royalties on net sales of partner-commercialized products. Its disclosed enterprise customers and partners include Catalent (2023 HILOPRO® licensing agreement for high-concentration biologics), Ipca Laboratories (2026 global licensing agreement for multiple mAb programs in oncology and inflammatory disease), and Indoco Remedies (contract work on the Naricover Naringin lozenge). The company serves three primary customer segments: biopharmaceutical companies developing monoclonal antibodies, peptide therapeutics developers seeking oral alternatives to injectables, and CDMOs seeking differentiated formulation capabilities. It is building direct enterprise sales coverage for the Americas via an open Business Development hire and holds DSIR-recognized R&D status valid until 2025.

Name

Bhami's Research Laboratory

Legal name

Bhami's Research Laboratories

Website

https://bhamilab.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Bhami's Research Laboratory is a Mangalore-based biotech that licenses proprietary HILOPRO® and Evopep drug delivery platforms to biopharmaceutical, peptide therapeutics, and CDMO partners for high-concentration subcutaneous and oral biologics delivery.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Delivery Technology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), DMPK / ADME & Bioanalysis (HLAGAFAC)

Keywords

• Drug delivery platforms
• Biologics formulation
• Subcutaneous delivery
• Oral peptide delivery
• Monoclonal antibody technology

Headquarters

HQ city

Mangaluru

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Licensing Fees and Technology Transfer: BRL licenses its proprietary platforms (HILOPRO® and Evopep) to pharmaceutical and biotech companies. Partners pay upfront licensing fees for technology access and transfer. Financial terms are typically undisclosed.
2. Milestone Payments: Partners pay milestone fees as development programs progress through key stages (preclinical, clinical trials, regulatory filings). BRL receives payments upon achievement of development milestones defined in licensing agreements.
3. Royalties on Commercial Sales: Upon commercialization of products developed using BRL's technology, the company earns royalties on net sales. This provides recurring revenue tied to the commercial success of licensed biopharmaceutical products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Bhami's Research Laboratory (BRL) develops and licenses two proprietary drug delivery technology platforms: HILOPRO®, a viscosity-reduction platform enabling high-concentration subcutaneous monoclonal antibody formulations up to 250 mg/mL using GRAS excipients, and Evopep, an oral biologics delivery platform for peptides and proteins that achieves 10-15% bioavailability in animal studies. The company generates revenue by licensing these patent-protected platforms to global pharmaceutical, biotech, and CDMO partners for development and commercialization of biologic therapies.

Product overview

Bhami's Research Laboratory (BRL) is a biotech company offering two core proprietary technology platforms: HILOPRO® for high-concentration subcutaneous biologic delivery and Evopep for oral biologic delivery. HILOPRO® uses patented GRAS excipients to reduce viscosity, enabling monoclonal antibodies to be delivered subcutaneously at concentrations up to 250mg/ml, offering patient-friendly administration compared to intravenous injections. Evopep is an oral delivery platform for peptides and proteins, achieving 10-15% bioavailability in animal studies. Additionally, BRL commercialized Naricover lozenges for Indoco Remedies. The company licenses these technologies to pharmaceutical partners including Catalent and Ipca Laboratories for development and commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• HILOPRO®: Proprietary high-concentration subcutaneous biologics delivery platform technology using GRAS excipients for monoclonal antibodies.
• Evopep

Products and services

• HILOPRO® Proprietary high-concentration subcutaneous biologics delivery platform using patented GRAS excipients to reduce viscosity and enable syringeable monoclonal antibody formulations at concentrations up to 250 mg/mL (with viscosity as low as 14cP). Validated on 9+ molecules including Trastuzumab, Rituximab, Bevacizumab, Etanercept, and Cetuximab, with proof of concept available in 8 weeks.
• Evopep Oral biologics delivery platform for peptides and proteins using GRAS excipients, demonstrating 10-15% bioavailability in in-vivo animal studies (at least 3x higher than Rybelsus®). Validated on peptides including Insulin, Glargine, HGH, Semaglutide, Liraglutide, PTH, and Octreotide; 8 out of 9 peptides showed great results in large animal models.
• Naricover Pharmaceutical lozenge product conceptualized and developed by BRL for Indoco Remedies Limited, containing Naringin (a citrus flavonoid with antiviral and anti-inflammatory properties) for treatment of suspected viral sore throats and dry coughs.
• Technology Licensing and Development Services BRL licenses its proprietary HILOPRO® and Evopep platforms to pharmaceutical, biotech, and CDMO partners under negotiated agreements comprising technology access fees, milestone payments during development, and royalties on net sales upon commercialization. Validated by 4 major biopharma players and currently licensed to Catalent and Ipca Laboratories.

Quantifiable outcome

• HILOPRO® enables 250mg/mL monoclonal antibody concentration with viscosity of only 14cP (vs. 20-30cP without technology)
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Ipca LaboratoriescoreStrategic or Co-development Partner · 13 June 2026Global licensing agreement for development and commercialization of multiple monoclonal antibody products targeting oncology and inflammatory diseases. Ipca will undertake R&D, clinical trials, and commercial manufacturing using BRL's high-concentration subcutaneous biologics delivery platform. BRL receives licensing fees for technology transfer plus royalties on net sales upon commercialization. Collaboration aims to accelerate affordable biologics for cancer and autoimmune disease patients worldwide.
• CatalentcoreOEM/ Whitelabel/ Licensing Partner · 19 March 2023Licensing agreement providing Catalent access to BRL's HILOPRO® formulation technology for viscosity reduction and high-concentration biologic delivery. Catalent is authorized to collaborate with its customers to evaluate the technology for monoclonal antibodies and fusion proteins. Successful programs may be integrated into Catalent's formulation and manufacturing services at scale. This partnership extends BRL's reach through Catalent's global CDMO customer base.
• Indoco Remedies LimitedminorStrategic or Co-development PartnerBRL conceptualized and performed studies on pharmaceutical lozenge product 'Naricover' for Indoco Remedies. The lozenges contain Naringin, a flavonoid with antiviral and anti-inflammatory properties for throat medications treating suspected viral sore throats and dry coughs.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Halozyme Therapeutics: Halozyme's ENHANZE® platform is the dominant high-concentration subcutaneous biologics delivery technology, used by Roche, Janssen, BMS, Pfizer, and others. It is the direct competitor to BRL's HILOPRO®, and the standard against which BRL positions its cost/performance claims.
• Alteogen: South Korean biotech developing subcutaneous and sustained-release delivery technologies for biologics, including a hyaluronidase-based platform competing with ENHANZE® and alternative SC formulation technologies overlapping with HILOPRO®.
• Rani Therapeutics: Develops an oral robotic pill (RaniPill) for delivery of biologics including peptides and proteins, directly comparable to BRL's Evopep platform in pursuing oral bioavailability for injectable biologics.

Emerging players

• Ascendis Pharma: Uses its TransCon prodrug/extended-release technology platform to enable sustained delivery of biologics including peptides and proteins. Overlaps with BRL's delivery-platform approach but uses transient conjugation rather than excipient-based formulation.
• Nektar Therapeutics: Develops PEGylation and polymer-conjugation technologies to extend half-life and improve delivery of biologics, including peptides. Comparable as a delivery-platform licensor serving pharma partners developing differentiated biologic formulations.
• BioAtla: Engineers Conditionally Active Biologics (CABs) for tumor-selective targeting, sharing the protein engineering and biologics platform-licensing business model that BRL applies to delivery rather than targeting.
• InnoCore Pharmaceuticals: Develops biodegradable sustained-release injectable polymer formulations for peptides and proteins, comparable to BRL's delivery-platform licensing model in addressing patient-friendly administration of biologics.

Broad incumbents

• Catalent: Global CDMO and BRL's named licensing partner for HILOPRO®. Catalent offers its own formulation and drug delivery capabilities across a broad portfolio, making it both a partner and a broad incumbent operating in adjacent biologics formulation services.
• Lonza: Global CDMO with biologics formulation, drug product, and delivery services serving pharma partners. Overlaps with BRL's positioning as a formulation technology provider serving biologics developers.
• WuXi Biologics: Major global biologics CDMO offering formulation and drug product development services across the biopharma value chain, comparable as a broad incumbent serving the same customer segment as BRL.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/BhamisResearch
• LinkedInlinkedin.com/company/bhamisreseachlab

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bhami's Research Laboratory